The effect of anti-CGRP antibody treatment on central sensitizatio
Not Applicable
- Conditions
- migraine
- Registration Number
- JPRN-UMIN000044096
- Lead Sponsor
- Tominaga Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with secondary headache except for medication overuse headache 2) Patients with trigeminal autonomic cephalalgias (TACs)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The improvement of central sensitization in migraine after 6 months of Galcanezumab treatment
- Secondary Outcome Measures
Name Time Method